Have a feature idea you'd love to see implemented?
Let us know!
FGEN Fibrogen Inc
Price (delayed)
$0.3111
Market cap
$31.23M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$1.71
Enterprise value
$91.44M
FibroGen, Inc. is a biopharmaceutical company committed to discovering, developing, and commercializing a pipeline of first-in-class therapeutics. The Company applies its pioneering expertise in hypoxia-inducible factor (HIF) and connective tissue
Highlights
The company's EPS rose by 50% YoY and by 30% QoQ
The net income is up by 48% year-on-year and by 30% since the previous quarter
FGEN's equity has dropped by 127% year-on-year
The quick ratio has contracted by 47% YoY and by 9% from the previous quarter
Key stats
What are the main financial stats of FGEN
Market
Valuations
Earnings
Shares outstanding
100.4M
Market cap
$31.23M
Enterprise value
$91.44M
Price to earnings (P/E)
N/A
Price to book (P/B)
N/A
Price to sales (P/S)
0.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.53
Revenue
$173.82M
EBIT
-$148.52M
EBITDA
-$142.67M
Free cash flow
-$202.99M
Per share
Balance sheet
Liquidity
EPS
-$1.71
Free cash flow per share
-$2.03
Book value per share
-$2.34
Revenue per share
$1.74
TBVPS
$2.94
Total assets
$293.2M
Total liabilities
$483.58M
Debt
$200.92M
Equity
-$232.34M
Working capital
$60.87M
Debt to equity
-0.86
Current ratio
1.41
Quick ratio
0.99
Net debt/EBITDA
-0.42
Margins
Efficiency
Dividend
EBITDA margin
-82.1%
Gross margin
76.7%
Net margin
-96.8%
Operating margin
-91.9%
Return on assets
-43.6%
Return on equity
N/A
Return on invested capital
-54%
Return on capital employed
-102.7%
Return on sales
-85.4%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
FGEN stock price
How has the Fibrogen stock price performed over time
Intraday
1.6%
1 week
-2.78%
1 month
-22.11%
1 year
-37.99%
YTD
-64.9%
QTD
-22.11%
Financial performance
How have Fibrogen's revenue and profit performed over time
Revenue
$173.82M
Gross profit
$133.23M
Operating income
-$159.66M
Net income
-$168.32M
Gross margin
76.7%
Net margin
-96.8%
Fibrogen's operating margin has soared by 63% YoY and by 35% from the previous quarter
The company's net margin has surged by 61% YoY and by 33% QoQ
FGEN's operating income has surged by 51% year-on-year and by 33% since the previous quarter
The net income is up by 48% year-on-year and by 30% since the previous quarter
Growth
What is Fibrogen's growth rate over time
Valuation
What is Fibrogen stock price valuation
P/E
N/A
P/B
N/A
P/S
0.18
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.53
The company's EPS rose by 50% YoY and by 30% QoQ
FGEN's equity has dropped by 127% year-on-year
The stock's price to sales (P/S) is 98% less than its 5-year quarterly average of 10.5 and 78% less than its last 4 quarters average of 0.8
The company's revenue rose by 33% YoY and by 3.8% QoQ
Efficiency
How efficient is Fibrogen business performance
The company's return on sales has surged by 65% YoY and by 36% QoQ
FGEN's return on invested capital is up by 48% year-on-year and by 23% since the previous quarter
FGEN's return on assets is up by 23% year-on-year and by 20% since the previous quarter
Dividends
What is FGEN's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for FGEN.
Financial health
How did Fibrogen financials performed over time
FGEN's total assets is 39% smaller than its total liabilities
The quick ratio has contracted by 47% YoY and by 9% from the previous quarter
FGEN's total assets is down by 43% year-on-year and by 20% since the previous quarter
The company's debt is 186% higher than its equity
FGEN's equity has dropped by 127% year-on-year
FGEN's debt to equity has soared by 57% YoY and by 3.4% from the previous quarter
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.